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Introduction: Colorectal cancer (CRC) is the second leading cause of cancer death
worldwide and most deaths result from metastases. We have analyzed animal models
in which Apc, a gene that is frequently mutated during the early stages of colorectal
carcinogenesis, was inactivated and human samples to try to identify novel potential
biomarkers for CRC.
Materials and Methods: We initially compared the proteomic and transcriptomic
profiles of the small intestinal epithelium of transgenic mice in which Apc and/or Myc
had been inactivated. We then studied the mRNA and immunohistochemical expression
of one protein that we identified to show altered expression following Apc inactivation,
nucleosome assembly protein 1–like 1 (NAP1L1) in human CRC samples and performed
a prognostic correlation between biomarker expression and survival in CRC patients.
Results: Nap1l1 mRNA expression was increased in mouse small intestine following
Apc deletion in a Myc dependant manner and was also increased in human CRC
samples. Immunohistochemical NAP1L1 expression was decreased in human CRC
samples relative to matched adjacent normal colonic tissue. In a separate cohort of
75 CRC patients, we found a strong correlation between NAP1L1 nuclear expression
and overall survival in those patients who had stage III and IV cancers.
Conclusion: NAP1L1 expression is increased in the mouse small intestine following
Apc inactivation and its expression is also altered in human CRC. Immunohistochemical
NAP1L1 nuclear expression correlated with overall survival in a cohort of CRC patients.
Further studies are now required to clarify the role of this protein in CRC.
Keywords: colorectal cancer, biomarkers, Apc, NAP1L1, prognosis, survival
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INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer type
and the second leading cause of cancer death worldwide (1).
Deaths usually result from recurrent and metastatic disease. Most
international guidelines recommend chemotherapy to reduce
the risk of recurrence in stage III tumors and to prolong
survival in stage IV cancers (2). Conversely, chemotherapy is
generally not used in stage I and most stage II tumors. However,
some patients with low-risk stage III disease may respond well
following courses of chemotherapy that are shorter than the
6-month standard schedule, although the definition of “low-
risk” has not been well established in this scenario (3, 4).
Additionally, almost 20% of patients who have stage II tumors
and who are therefore considered to have low-risk disease,
relapse and eventually die from cancer progression (5). There
is currently no accurate biomarker to better define prognosis
within stage groups. Therefore, biomarkers for prognostic
stratification in CRC have the potential of improving the
treatment decision-making process (4, 6). We hypothesized that
studying molecular mechanisms that are known to be involved
in CRC development might yield promising novel biomarkers
for this disease.
Adenomatous polyposis coli (APC) inactivating mutations
are the earliest and most common genetic alterations in the
adenoma-carcinoma sequence that leads to CRC (7). Such
mutations result in the accumulation of β-catenin within cells
and activation of the Wnt signaling pathway (8). Animal
models of Apc inactivation demonstrate epithelial transformation
and tumor formation mirroring cancer development (9–
11). One of these models is the AhCre+Apcfl/fl mouse,
an animal bearing loxp-flanked Apc alleles and a Cre-
recombinase transgene. When this animal is exposed to
β-naphthoflavone, Cre-recombinase transcription is activated
resulting in the deletion of loxp-flanked Apc alleles specifically
in the small intestinal epithelium, thus causing an acute
activation of the Wnt pathway (9). The ApcMin/+ mouse has
a germline mutation in one Apc allele simulating a familial
adenomatous polyposis (FAP) patient, and spontaneously
develops multiple intestinal neoplasms during its life-span (12,
13). The Myc gene is a Wnt-target that plays an essential
role in the development of malignant phenotypes upon Apc
inactivation (14, 15). We hypothesized that the analysis of
mouse models of Apc and Apc/Myc deletion could lead to the
discovery of genes or proteins with potential clinical use as
human CRC biomarkers.
Our group has previously published a proteomic evaluation
of an animal model of CRC based on acute Apc deletion
(AhCre+Apcfl/fl mouse) (16). A 4-plex iTRAQ labeling analysis
identified 126 proteins that were significantly altered upon
Apc deletion (76 up- and 50 down-regulated) and which
were proposed as Wnt targets. We have now performed an
additional analysis of this dataset by comparing the protein
list with the transcriptomic data generated using Affymetrix
arrays and intestinal tissues from the same mice (14). This
study used Apc–deficient (AhCre+Apcfl/flMyc+/+) and double-
mutant Apc-Myc deficient (AhCre+Apcfl/flMycfl/fl) mice
to identify Myc dependant Wnt pathway genes following
Apc inactivation. We investigated whether there were any
genes/proteins that showed congruent findings in both
analyses according to strict criteria. One protein, nucleosome
assembly protein 1 like 1 (NAP1L1) was identified that
met our criteria.
We therefore analyzed the expression of Nap1l1 in Apc–
deficient (AhCre+Apcfl/flMyc+/+) and double-mutant Apc-Myc
deficient (AhCre+Apcfl/flMycfl/fl) mice to assess whether its
expression was Myc-dependant and therefore a potential
biomarker of Wnt activation. Following confirmation of our
findings, we investigated the mRNA and protein expression
of NAP1L1 in tumor and adjacent normal mucosa samples
from patients with CRC as well as colonic tissues from
unaffected individuals.
MATERIALS AND METHODS
Animal Samples
Mouse experiments were performed with UK Home Office
approval with personal and project licenses (30/2737 and
30/3279) and according to ARRIVE guidelines and following
local ethical review by the Cardiff University Animal Welfare
Ethical Review Panel. The transgenic mice that were used in this
study were generated and maintained at the University of Cardiff
as previously described in (14). Small intestinal epithelial cell
extracts were generated from these mice following injection of
beta-naphthlaflavone as described by Hammoudi et al. (16).
qPCR RT-PCR
For the mouse small intestinal tissue samples and human
CRC samples obtained in the United Kingdom (Wales cohorts
1 and 2), total RNA was used to synthesize first strand
cDNA using a VersoTM cDNA Kit (Thermo Scientific) and
anchored oligo-dT primers (Thermo Scientific) according to
the manufacturer’s instructions. Single-stranded cDNA samples
were amplified in a Polymerase chain reaction (PCR) using
sequence-specific primers (Eurogentec) and probes from the
Universal Probe Library (Roche) that were designed using the
Universal ProbeLibrary Assay Design Centre, using PCR Master
mix (Roche) and a light cycler 480 (Roche) (see Supplementary
Table 2 for primers and probes used).
For the human CRC samples recruited in Brazil, RNA
was extracted using the RNeasy R© Mini Kit (Qiagen, Hilden,
Germany). cDNA was produced using TaqMan R© Reverse
Transcription Reagents kit (Applied Biosystems, Carlsbad,
CA, United States) according to the manufacturer’s protocol.
Quantitative PCR reactions were performed using the 7500 Fast
Real-Time PCR System (Applied Biosystems, Foster City, CA,
United States) (see Supplementary Table 3 for expression assay
specifications).
Proteomic and Microarray Comparison
Analysis
We set out to determine the subset of genes/proteins,
which demonstrated upregulation of both protein and mRNA
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following Apc deletion, but no increase in expression in
AhCre+Apcfl/flMycfl/fl mice. The MAXD/View-Program data
files from the microarray analyses were used to calculate gene
expression fold changes in the intestinal tissues from the various
transgenic mice. These data were then combined with our
previously published proteomic profile data (14) in which we
identified proteins which showed a greater than 1.2 fold increase
in expression following Apc deletion, using iTRAQ analysis.
The following features from the DNA microarray analysis
were used to identify candidate Myc dependant Wnt pathway
proteins: (i) a statistically significant (p < 0.05) greater than
2 fold increase in expression in Apc–deficient (AhCre+Apcfl/fl)
mice compared to wild-type mice (APC:WT); (ii) no significant
increase in expression in the double-mutant Apc-Myc deficient
(AhCre + Apcfl/fl Mycfl/fl) mice when compared to the wild-
type mice (a ratio value of 1:1, with boundaries of 0.75 and
1.25) (APCMYC:WT) and (iii) a AhCre+ Apcfl/fl Mycfl/fl to
AhCre+Apcfl/fl, ratio < 0.5 with p < 0.05 (APCMYC:APC) and
findings being confirmed by at least three Affymetrix probes
corresponding to the protein.
Human Samples and Ethics
United Kingdom Cohorts
Total RNA samples from CRC tumor tissues and adjacent
uninvolved colonic mucosa (18 patients) were obtained from
the Wales Cancer Bank (Wales cohort 1) with the ethical
approval and informed consent that is associated with this
tissue bank, and these samples were used in the initial gene
expression studies. There were 9 male and 9 female patients,
with 6 samples from stage I, 6 from stage II and 6 from
stage III CRC and mean patient age was 69.3 years. Another
set of 30 matched sample pairs was subsequently obtained
from the same Tissue Bank (Wales cohort 2) and these
were analyzed separately for validation of the findings. Wales
cohort 2 had 9 samples with stage I, 8 samples with stage
II and 13 samples with stage III CRC and the mean patient
age was 69.4 years.
A tissue microarray (TMA) was constructed using samples
from 19 CRC patients recruited at the Countess of Chester
Hospital NHS Foundation Trust (Chester, United Kingdom)
again with informed consent and local ethics committee approval
(12/NW/0011). Cancer tissues were available for all cases (5 cases
with stage I, 3 cases with stage II, 5 cases with stage III and 6 cases
with stage IV CRC), whilst normal adjacent mucosa was only
obtained for 8 of them. The analysis of this cohort was part of the
immunohistochemistry (IHC) validation study and the findings
are presented in Supplementary Figure 2.
Brazil Cohort
Fresh frozen tissues from tumors removed from 25 CRC patients
and normal colonic tissues from 10 normal individuals (who had
a normal colonoscopy on a bowel cancer screening program)
were collected, after informed consent was obtained, and were
analyzed in the gene expression studies. The CRC samples were
from 17 males and 8 females with stage I: 7; II: 3; III: 8 and IV:
7 CRC and the mean patient age was 55.9 years. The normal
samples were from 3 males and 7 females and the patients had
a mean age of 54.7 years.
For the initial Brazilian IHC study, samples from 32
patients were prospectively collected in Cuiaba – Brazil between
January 2013 and August 2015. Informed consent was obtained.
Fragments from the tumor and from the normal adjacent mucosa
(at least 10 cm from the tumor) were fixed in 10% buffered
formalin for 24 h, and then processed into paraffin blocks. Patient
characteristics are described in the results section below.
For the IHC prognostic study, samples were obtained for 75
CRC patients from the archives of two pathology laboratories
in Cuiaba, Brazil (Laboratorio São Nicolau and the Julio Muller
University Hospital Pathology Lab). Inclusion criteria were: (i)
4 or more years since diagnosis, (ii) presence of tumor tissue in
the paraffin block, (iii) traceable patient survival information, and
(iv) survival for at least 30 days after surgery. We tracked the
patient’s current health service to obtain mortality information.
Alternatively, if no clinical information was available, we checked
the Brazilian electronic death database “Sistema de Informacao
de Mortalidade” which records all deaths and their causes.
Overall survival was recorded as the interval between diagnosis
and death from any cause (when death had occurred) or
the date when the database was last checked (when death
had not occurred).
This research was approved by the Committee for Research
Ethics of the Hospital Universitario Julio Muller – Federal
University of Mato Grosso, Cuiaba – Brazil, and by the Brazilian
National Commission for Research Ethics (CONEP), decision
number: 1.628.901.
Immunohistochemistry in the Validation
Study
Four µm sections from paraffin blocks were subjected to
standard protocols for IHC. Tris-buffered saline-tween
0.1% (TBS-T) was used for all washes. In summary the
main steps were: dewaxing in xylene twice; endogenous
peroxidases block using 3% hydrogen peroxide in methanol;
rehydration in decreasing concentrations of ethanol solutions
and, finally, distilled water; heat-induced epitope retrieval
using 10 mM citrate buffer pH 6.0 in a microwave oven
at 800 W for 20 min; block using 10% normal goat serum
(Dako, Ely, United Kingdom) in TBS-T for 45 min at room
temperature; primary rabbit anti-NAP1L1 antibody (cat. number
ab33076, Abcam, Cambridge, United Kingdom) 1:4,000 in 10%
normal goat serum in TBS-T overnight at 4◦C in a humid
chamber; biotinylated secondary goat anti-rabbit antibody
(Dako, Ely, United Kingdom) solution 1:200 in 10% normal
goat serum for 30 min at room temperature; avidin-biotin-
peroxidase complex (Vectastain Elite ABC kit – Peterborough,
United Kingdom) for 30 min at room temperature; visualization
using 3,3′-diaminobenzidine (Sigmafast DAB tablets – Sigma,
Gillingham, United Kingdom) substrate solution; application
of hematoxylin counterstain; dehydration in increasing
concentrations of ethanol; clearing in xylene and mounting
using DPX mounting medium (Sigma) and glass coverslips.
Stained sections were viewed and photographed using a
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microscope and camera set (Leica Biosystems, Milton Keynes,
United Kingdom). The same staining protocol was used for
the additional United Kingdom patient cohort described in
Supplementary Figure 2.
Immunohistochemistry in the Prognostic
Study
The protocol adopted in this part of the research was
the routine technique used in the São Nicolau Laboratory
(Cuiaba/Brazil), a pathology lab with extensive expertise in IHC.
All branded solutions and buffers were purchased from Cell-
MarqueTM/Sigma-Aldrich (Rocklin, CA, United States). Four
µm tissue sections were dewaxed in xylene and rehydrated
as previously described. After a wash step in distilled water,
slides were immersed in TrilogyTM pre-treatment solution and
incubated at 96◦C for 30 min for epitope retrieval. After this, the
slides were washed in phosphate buffered saline (PBS), Peroxide
blockTM solution was added and samples were incubated for
20 min. After another PBS wash, the primary antibody solution
(same concentration as those described above) was placed onto
the samples and incubated for 20 min at room temperature. After
washes in PBS, HiDef DetectionTM amplifier (secondary antibody
solution) was applied to the slides for 15 min. After a further
PBS wash, the former step was repeated using HiDef DetectionTM
detector (a horseradish peroxidase polymer solution). Finally,
color development was performed by incubating the slides with
DAB substrateTM chromogen. Stained slides were counterstained,
dehydrated and mounted as described above. Slides were
photographed using an Axio Scope.A1 microscope coupled with
an AxioCamHRc camera (Zeiss, Oberkochen, Germany). Some
samples were stained using both the protocol described here and
that in the previous section and these confirmed that the staining
patterns were similar (see Supplementary Figure 1).
Immunohistochemistry Scoring System
Scoring was performed electronically using the software ImageJ
(publicly available at rsbweb.nih.gov/ij/) (IMAGEJ). The images
were initially edited in Image J to exclude non-epithelial/non-
cancerous/stromal tissues. For cytoplasmic assessment, the
plugin IHC Profiler was used (17). Based on the readings
produced by this tool, we calculated a modified IHC Profiler
score = [(% of negative)× 0] + [(% of low-positive)× 100] + [(%
of positive) × 200] + [(% of high-positive) × 300], with final
scores ranging from 0 to 300. For nuclear scoring, the plugin
ImmunoRatio was used (18). It assesses the percentage of positive
nuclei based on a threshold setting. Two microscopy fields
(×400) containing at least 100 stained epithelial (in control cases)
or cancer cells each were analyzed per sample.
Statistical Analysis
Comparisons of continuous variables were carried out using
Mann–Whitney U test or Kruskal–Wallis test followed by the
Dunn-Bonferroni test for post hoc comparison. Categorical data
were compared using the Chi-square test (or Fisher’s exact test in
case of less than five expected counts per cell in the contingency
table). For the survival analysis, groups were assessed using the
Kaplan-Meier method, and survival curves were compared by
log-rank tests. When significant differences were observed, Cox
proportional hazards model was used for multivariate analysis.
Two-sided p-values <0.05 were accepted as significant in the
entire study. All statistical analyses were performed using the
software IBM R© SPSS R© Statistics version 22 and R packages.
RESULTS
Combination of Proteomic and
Transcriptomic Datasets
Our previously published proteomic data (14) was integrated
with the DNA microarray data from the double-mutant Apc-
and Myc-deficient (AhCre+Apcfl/flMycfl/fl) mice as shown in
Supplementary Table 1. Of the 93 up-regulated proteins from
the iTRAQ analysis, only one also showed up-regulation of
mRNA in the intestine of AhCre+Apcfl/flMyc+/+ mice and no
change in the intestine of AhCre+Apcfl/flMycfl/fl mice using the
criteria described in the Materials and Methods section. This
protein was NAP1L1.
Evaluation of Nap1l1 mRNA Expression
in Mouse Small Intestine
In order to validate whether Nap1l1 mRNA was upregulated
following conditional Apc deletion in the mouse intestinal
epithelium, qRT-PCR was carried out using mRNA
extracted from small intestinal epithelial cell extracts from
AhCre+Apcfl/f Mycfl/fl, AhCre+Apcfl/fl, and AhCre+Mycfl/fl
mice, 4 days post induction. We compared relative mRNA
expression in these transgenic mouse cohorts with the mRNA
expression levels in AhCre+Apc+/+Myc+/+ (wild-type) mice.
Results are shown as fold change relative to the wild-type
mice (Figure 1). This analysis confirmed that Nap1l1 mRNA
expression was significantly increased following Apc deletion in
a Myc-dependent manner.
Evaluation of NAP1L1 mRNA Expression
in Human Colorectal Cancer Samples
NAP1L1 was then analyzed in three cohorts of human CRC
samples. We assessed the expression of NAP1L1 firstly in mRNA
from CRC tissues and matched normal mucosa from 18 patients
supplied by the Wales Cancer Bank. NAP1L1 demonstrated
statistically significant elevated mRNA levels in CRC samples
(Figure 2, Wales cohort 1). We next performed a confirmatory
study using a different set of 30 samples from the same Tissue
Bank, and we observed consistent results (Figure 2, Wales cohort
2). In order to further validate the findings, we repeated the
experiment using a different platform (in terms of equipment and
reagents) and compared a cohort of 10 normal colonic samples
(individuals without any colonoscopic evidence of colorectal
neoplasia) and 25 CRC samples from Brazil (Figure 2, Brazil
cohort). Once more, significantly increased levels of NAP1L1
mRNA were observed in CRC specimens and this time the
comparison was with normal colonic tissue from patients who
had no evidence of colorectal neoplasia.
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FIGURE 1 | Relative expression of Nap1l1 mRNA extracted from small
intestinal epithelial samples from induced AhCre+Apc+/+Myc+/+,
AhCre+Apcfl/fl, AhCre+ Apcfl/fl Mycfl/fl, and AhCre+Mycfl/fl mouse models
(four mice in each group) showing the fold change in mRNA expression for
each gene relative to AhCre+Apc+/+Myc+/+. Error bars: standard error (SE).
p < 0.05 for AhCre+Apcfl/fl compared to other groups.
FIGURE 2 | qPCR analysis of NAP1L1 expression in CRC tumors presented
as fold-change relative to normal tissues in different cohorts. Each column
represents the relative quantification (fold-change) of NAP1L1 mRNA
expression in CRC compared to the respective normal control (normal control
expression mean = 1). Wales cohort 1, mean fold-change = 2.7; p < 0.05 (18
paired colorectal cancer and adjacent normal colonic tissue samples). Wales
cohort 2, mean fold-change = 5.8; p < 0.001 (30 paired colorectal cancer
and adjacent normal colonic tissue samples). Brazil cohort, mean
fold-change = 7.9; p < 0.001 (10 normal samples from healthy individuals
without colorectal neoplasia and 25 colorectal cancer samples).
Mann–Whitney U test. Error bars: ±1 SE.
Confirmation of Differential
Immuno-Expression of NAP1L1 in
Human Colorectal Tissues
Immunohistochemistry for NAP1L1 was then performed in
colorectal tissue samples from a different cohort of 32 patients, as
described in section “Materials and Methods.” Cancer tissues and
the matched unaffected mucosa collected 10 cm from the primary
lesion were analyzed. Scoring was performed electronically using
the software ImageJ (publicly available at rsbweb.nih.gov/ij/) and
the plugins IHC Profiler for cytoplasmic scoring (resulting in a
modified H-score ranging from 0 to 300)(17) and ImmunoRatio
for nuclear scoring (ranging from 0 to 100%)(18). The samples
were subdivided into two groups who had early stage (11 samples
encompassing stages I and II) and late stage (21 samples including
stages III and IV) CRC.
We initially assessed the expression of β-catenin to confirm
Wnt pathway activation and to validate the electronic scoring
methods (Figure 3). A clear and statistically significant increase
in both nuclear and cytoplasmic localization of β-catenin was
observed in cancer tissues compared to the adjacent mucosa, as
expected based on previous literature (19–21), thus validating our
scoring system. Using the same scoring methods, we observed an
opposite staining pattern for NAP1L1. A clear and statistically
significant decrease in both the nuclear and cytoplasmic
expression of NAP1L1 was seen in CRC tissues relative to the
adjacent mucosa (Figure 4). No difference was detected between
early and late stage tumor groups for both markers.
We also performed a confirmatory analysis using a different
cohort of 19 patients from the Countess of Chester Hospital
NHS Foundation Trust (Chester, United Kingdom). This analysis
used a slightly different manual scoring method as described
in Supplementary Figure 2. The findings were very similar
to those demonstrated in the Brazilian patients and again
demonstrated decreased NAP1L1 expression in the CRC samples
(Supplementary Figure 2).
NAP1L1 Nuclear Expression Is a Strong
Predictor of Survival in Late Stage CRC
Having demonstrated decreased NAP1L1 immunohistochemical
expression in CRC samples, we investigated whether the
expression pattern had any effect on patient outcome. We
analyzed a further cohort of 75 CRC cases diagnosed between
2004 and 2012. Median follow-up was 84.7 months (range 48–
153 months). Given the relatively small number of cases, cancer
stages were again combined into two groups: early stage (stages I
and II) and late-stage (stages III and IV). Immunohistochemistry
was conducted as described in section “Materials and Methods.”
Table 1 describes the characteristics of the patients included in
this analysis.
Initially, using mortality status as the binary event of interest,
ROC curves were generated. The area under the curve (AUC)
was 0.58 for the nuclear score and 0.60 for the cytoplasmic
score. Cut-offs were determined either by manually assessing the
best balance between sensitivity and specificity or electronically
by the use of the software Cutoff Finder (22) and X-Tile (23).
All methods suggested the same cut-off for nuclear staining:
32% (of positive nuclei). Use of this threshold resulted in a
sensitivity of 61% and a specificity of 67.5% for discriminating
mortality status. For cytoplasmic staining, sensitivity/specificity
optimization suggested a cut-off of 135 (in a range from 0
to 300), yielding a sensitivity of 57% and a specificity of
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FIGURE 3 | Staining patterns and scoring results for β-catenin. Nuclear and cytoplasmic staining of β-catenin increased in cancer tissues when compared to the
adjacent mucosa. No difference was observed between different stages of cancer. ***p < 0.001 (Kruskal–Wallis test followed by post hoc Dunn-Bonferroni test for
pair-wise comparisons). Error bars: ±2 SE. Sample numbers: normal = 32, stages I–II = 11, stages III–IV = 21. Magnification: 630×.
54%. The electronic tools suggested higher cut-offs (167 and
168). Although these resulted in a higher specificity (92%),
the sensitivity was low (29%). Despite these differences, the
prognostic results were similar, so the cytoplasmic cut-off of 135
was selected to describe the results.
The prognostic cohort was therefore divided into two groups
with low-expression and high-expression of NAP1L1. Groups
were similar in terms of age, gender, stage and grade. Table 2
shows the clinicopathological characteristics of the groups
according to the nuclear expression of NAP1L1. Similar balanced
distribution was also observed for cytoplasmic expression.
Using the Kaplan–Meier method, cumulative survivals for the
two groups (high and low nuclear expression) were compared.
Initially, groups were assessed as a whole, regardless of disease
stage (Figure 5A). A clear difference in cumulative survival was
observed according to nuclear NAP1L1 staining (p = 0.012, log-
rank test). In the multivariate analysis including age, gender,
stage and grade (Cox proportional hazards model), the nuclear
score was independently associated with cumulative survival. The
high nuclear expression group exhibited a hazard ratio (HR):
0.39 ([95%CI: 0.17–0.87]; p = 0.02), denoting a 61% reduction
in cumulative mortality in this group. As a result, the estimated
5-year survival was 44.4% in the low expression group and
75% in the high expression group. Median duration of survival
was 32 months in the low expression group, whilst it was not
reached for the high expression cohort. The only additional
variable also associated with survival was tumor stage (HR: 2.55
[95%CI: 1.01–6.43]; p = 0.047), an expected finding since stage is
a known prognostic factor in CRC. These results strongly suggest
an association between NAP1L1 nuclear staining and survival
in CRC patients. Conversely, cytoplasmic NAP1L1 staining was
not associated with survival (Figure 5B) or with any other
clinicopathological variable.
We then analyzed survival according to NAP1L1 nuclear
expression in different stage groups (Figures 5C,D). For early
stage disease, no significant difference in survival was found. By
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FIGURE 4 | Staining patterns and scoring results for NAP1L1. NAP1L1 nuclear and cytoplasmic scores were decreased in the cancer groups when compared to
normal adjacent tissues. No difference was observed between different stages of cancer. ***p < 0.001 (Kruskal–Wallis test followed by post hoc Dunn-Bonferroni
test for pair-wise comparisons). Error bars: ±2 SE. Sample numbers: normal = 32, stages I–II = 11, stages III–IV = 21. Magnification: 630×.
contrast, a highly significant difference in survival was observed
for the cohort containing stages III and IV tumors. Multivariate
analysis once again demonstrated that NAP1L1 nuclear score was
an independent prognostic factor in CRC patients. The calculated
HR (0.28 [95%CI: 0.11–0.71]; p = 0.008) was even more notable
than that observed for the entire cohort, now suggesting a 72%
reduction in cumulative mortality. The 5-year survival advantage
for high expression tumors was also greater: 70%, versus 34% for
low expression cancers. Median survival was only 23 months in
the low expression group and, again, was not reached in the high
expression cohort.
DISCUSSION
The discovery of novel CRC biomarkers to assist in early
diagnosis, prognostic stratification and prediction of response
to treatment remains an unmet medical need. We hypothesized
that the study of animal models of CRC based on transgenic Apc
gene inactivation could lead to the discovery of novel useful CRC
biomarkers in humans.
By combining transcriptomic and proteomic analyses of small
intestinal tissue from transgenic mice in which Apc and/or Myc
had been specifically deleted, we identified NAP1L1 as the only
gene/protein that showed significantly altered expression in Apc
and Myc-dependent manners in all analyses. We confirmed these
findings using qPCR in mouse small intestine and additionally
demonstrated that NAP1L1 mRNA expression was increased
in human CRC. It was unfortunately not possible to study
whether there was any altered NAP1L1 expression in the colon
of the AhCre mouse model as there is no Cre mediated
recombination in the colon of these mice following injection of
β-naphthoflavone and they have no colonic phenotype (24).
NAP1L1 is a highly conserved histone chaperone protein
which is one of five NAP1-like proteins in mammals (21, 22).
It has been suggested to play a role in mediating nucleosome
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TABLE 1 | Characteristics of the patients included in the prognostic analysis.
Characteristics Patients (n = 75)
Mean age (range) 59.7 (33− 84)
Gender
Male 43 (57.3%)
Female 32 (42.7%)
Stage
I–II 28 (37.3%)
III–IV 47 (62.7%)
Grade
Well differentiated 23 (30.6%)
Moderately differentiated 50 (66.6%)
Poorly differentiated 2 (2.6%)
TABLE 2 | Clinicopathological characteristics according to NAP1L1
nuclear expression.
Characteristics Low nuclear
expression
(n = 34)
High nuclear
expression
(n = 41)
Two-sided
p-values
Mean age 61.9 57.8 0.157
Gender 0.648
Male 17 24
Female 16 18
Stage 0.338
I–II 10 18
III–IV 23 24
Grade . 14 0.351
Well differentiated 9 14
Mod differentiated 24 26
Poorly differentiated 0 2
No significant difference between groups was observed. Mean age was compared
by t-test. Categorical variables were compared by Chi-square test or Fisher’s exact
test.
formation and regulation of the H2A-H2B complex as well
as nucleosome assembly (25), cell cycle progression, and cell
proliferation (26). It has also been linked to embryogenesis and
tissue differentiation (23–25). Few researchers have previously
studied NAP1L1 expression in cancer cell lines or tissues.
Drozdov et al. compared small intestinal neuroendocrine tumors
(NETs) and normal enterochromaffin cell preparations, and
showed a 13.7-fold increase in NAP1L1 expression in tumor
tissues (27). However, no analysis of the adjacent mucosa
was performed. Kidd et al. also suggested that NAP1L1 was
increased in NETs but not in CRCs (28). Line et al. evaluated
NAP1L1 mRNA expression in CRC and adjacent tissues as
a secondary endpoint in a study primarily aimed at finding
sero-reactive biomarkers (29). They showed that, among 15
cases of CRC, seven exhibited moderate increases in NAP1L1
expression (ranging from 2.9 to 9.3-fold) and eight cases showed
expression levels similar to those in the corresponding adjacent
mucosa. A recent paper has also demonstrated that NAP1L1
is a prognostic biomarker and contributes to doxorubicin
chemotherapy resistance in hepatocellular carcinoma (30).
Immunohistochemistry is used in routine clinical practice to
assess the expression of proteins with prognostic or predictive
value in other types of cancer such as breast (31) and lung
carcinomas (32), soft tissue sarcomas (33), and lymphomas (34).
Given the absence of a standard scoring method for NAP1L1, we
initially decided to assess both the nuclear and the cytoplasmic
expression of the protein in our samples using electronic tools.
Our results showed that NAP1L1 expression was decreased both
in the nucleus and the cytoplasm of CRC tissues when compared
to the normal adjacent mucosa.
This was a somewhat unexpected finding, given the increased
expression of NAP1L1 mRNA in animal models and in human
tissues. Such discrepancy between mRNA and protein expression
has however previously been demonstrated for other cancer
markers (35–37). Several processes could be responsible, such as
posttranscriptional modifications, protein degradation, secretion
via exocytosis or alterations in subcellular protein localization.
For example a recent paper has reported that NAP1L1 undergoes
alternative cleavage and polyadenylation in the more advanced
stages of CRC (38). The full length isoform of NAP1L1 was
overrepresented in the cytoplasmic fraction of a CRC cell line
which had a more metastatic phenotype. This may therefore
represent one mechanism to explain the altered NAP1L1
subcellular localization that is reported in CRC specimens
in our current manuscript. Counterintuitively, our finding of
increased gene expression in the initial screen may have been a
response to reduced protein content and not the primary event.
Further research is required in order to clarify this issue. Qiao
et al. (39) demonstrated that knock down of NAP1L1 increased
cellular proliferation, disrupted normal cell development and
distribution, and caused global deregulation of gene expression.
These are classical hallmarks of cancer and of activated Wnt
signaling. Qiao et al. also demonstrated that Nap1l1 knockdown
resulted in reduced RassF10 expression, low expression of which
has been associated with poor survival in CRC patients in another
study (40). Thus reduced NAP1L1 protein expression could be
mechanistically associated with tumor progression.
We also assessed whether NAP1L1 expression was associated
with prognosis. We retrospectively retrieved blocks from a cohort
of CRC patients with more than 4 years follow up. Cut-offs for
nuclear and cytoplasmic expression of NAP1L1 were established
and a survival analysis was performed. Nuclear expression of
NAP1L1 correlated with overall survival in CRC. High nuclear
expression was independently associated with an increase in
median survival and 5-year survival estimates. Subgroup analysis
however showed that the survival correlation was limited to late
stage tumors (stages III and IV). No association between NAP1L1
nuclear expression and clinicopathologic variables (age, gender,
stage and grade) was observed. These findings suggest that the
expression of NAP1L1 could potentially help in discriminating
low and high-risk disease in stage III CRC cases and, also, to
determine the aggressiveness of the disease in stage IV cancers.
In both cases, this information could help to better define the best
treatment approach.
We acknowledge some limitations in this study. Although
positive and relevant findings were observed, the use of small
clinical sample sizes may have limited our observations. This
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FIGURE 5 | Cumulative survival according to NAP1L1 expression. In panel (A), nuclear staining is assessed. A highly significant (p = 0.012) and clinically relevant
(HR = 0.39 [95%CI: 0.17–0.87]) difference in survival between groups was observed favoring the high expression group. In panel (B), cytoplasmic staining, no
significant difference was observed. In panel (C), nuclear expression for early stage disease (stages I and II) is assessed. No difference in survival was observed.
Panel (D) shows the results for late stage disease (stages III and IV). A statistically significant difference was observed favoring the high nuclear expression group
(HR: 0.28 [95%CI: 0.11–0.71]). Squares and circles = censored cases. HR: hazard ratio. CI: confidence interval.
also meant that it was necessary to evaluate cancer stages as
combined groups rather than individually. Better prognostic
stratification in stage II disease is urgently needed to improve the
treatment decision-making process and our data did not permit
this. Moreover, analyzing larger cohorts of stage III and stage IV
diseases separately would also be desirable, as these stages are
associated with markedly different clinical outcomes.
This study provides proof of concept that the analysis
of animal models of Wnt pathway activation may yield
potentially useful CRC biomarkers in humans. We undertook
a comprehensive assessment of NAP1L1 expression in animal
models and clinical samples and our findings suggest that
it could be a prognostic biomarker for CRC. Confirmatory
research studying larger sample cohorts and a better assessment
of the role of this protein in CRC carcinogenesis is now
recommended before this marker can be introduced routinely
into clinical practice.
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